Kaligia Bioflector (KBS-1)
The Kaligia BioFlector (KBS-1) works beyond merely considering spectral measurements through the skin; It recognizes the proven correlation of other variates with blood glucose values. This information significantly increases the accuracy of glucose predictions.
Our technology aims to assist patients and caregivers in managing and monitoring their vitals in a more convenient way. The technology will assist medical practitioners and supporting staff in offering superior patient care while saving time and resources by avoiding traditional diagnostics and management.
KBS-1 is designed to assist providers directly, Kaligia is focusing on nursing homes and hospitals as their initial target market.
A growing problem requires constant monitoring and analysis
The American Diabetes Association states 25% of the 65+ population in the United States has diabetes, a shocking statistic. The International Diabetes Federation pegs the number of diabetics worldwide at 386 million.